SMYD2 mRNA expression level is associated with metastatic relapse in the relapse-free survival of breast cancer patients, indicating that SMYD2 acts as a potential biomarker and prognostic indicator for this cancer [55]. Here, SMYD2 is linked to breast carcinoma.